Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition
Background: In a preliminary trial, we assessed the efficacy of vortioxetine for major depressive disorder (MDD) during the menopausal transition. Secondary outcomes included hot flashes (HFs), anxiety, and cognitive complaints. Methods: Perimenopausal and early postmenopausal women […]
